A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab(Anti-PD-1) and Ociperlimab(Anti-TIGIT) as First-line Treatment in Participants With Unresectable Advanced BTC
Overview
- Phase
- Phase 2
- Intervention
- GP+PD-1+Tight
- Conditions
- Intrahepatic Cholangiocarcinoma
- Sponsor
- Fudan University
- Locations
- 1
- Primary Endpoint
- Objective response rate (ORR)
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of GP (Gemcitabine/Cisplatin) in combination with Tislelizumab and Ociperlimab as first-line treatment in participants with unresectable advanced Biliary Tract Carcinoma (BTC).
Detailed Description
Biliary Tract Carcinoma (BTC) have insidious onset, invasiveness, high malignancy, and no specific symptoms in the early stage, and most of them are in the middle and advanced stages at the time of diagnosis and have lost the chance of surgery. For patients with advanced BTC, systemic therapy is currently the main choice, and gemcitabine/cisplatin (GP) is currently the "gold standard" for first-line treatment of advanced BTC, but the efficacy is still unsatisfactory, and more and more clinical practice has found that GP-based combination therapy may have better efficacy. Previous studies have shown that chemotherapy can improve the immunotherapy microenvironment and may have a synergistic anti-tumor effect in combination with immunotherapy. This study is to explore the efficacy and safety of GP in combination with anti-PD1 antibody (Tislelizumab) and anti-TIGIT antibody (Ociperlimab) as first-line treatment in participants with unresectable advanced BTC.
Investigators
Jia Fan
Professor
Fudan University
Eligibility Criteria
Inclusion Criteria
- •• Subjects with a histopathological or cytologically diagnosis of BTC
- •The participants must be required to sign an informed consent
- •At least one measurable lesion (RECIST 1.1)
- •No previous systematic treatment for BTC
- •Child-Pugh Score, Class A
- •ECOG performance status 0 or 1
- •Adequate organ function
- •Life expectancy of at least 3 months
Exclusion Criteria
- •• Diagnosis of mixed ampullary, hepatocellular and cholangiocarcinoma
- •Known history of serious allergy to any monoclonal antibody
- •Known central nervous system metastases and/or leptomeningeal disease prior to treatment
- •Portal hypertension with esophageal or gastric varices within 6 months prior to initiation of treatment
- •Any bleeding or thrombotic disorder within 6 months prior to initiation of treatment
- •Any active malignancy prior to the start of treatment
- •Active or history of autoimmune disease
- •Other acute or chronic conditions, psychiatric disorders, or laboratory abnormalities that may increase the risk of study participation
- •Pregnant or lactating women
Arms & Interventions
GP+PD-1+Tight
Experimental: Tislelizumab 200mg IV Q3W + Ociperlimab 900mg IV Q3W + GP (gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W) Gemcitabine/Cisplatin will be administered on D1/D8 in every three weeks cycle and up to 8 cycles. Tislelizumab and Ociperlimab will be administered on D1 in every three weeks cycle, until the disease progression, intolerable toxicity, death, withdrawal of consent.
Intervention: GP+PD-1+Tight
Outcomes
Primary Outcomes
Objective response rate (ORR)
Time Frame: 24 months
ORR is defined as the proportion of subjects with complete response (CR) or partial response (PR) to study drugs.
Secondary Outcomes
- 6-months/12-months PFS rate(12 months)
- Overall Survival (OS）(24 months)
- Disease control rate (DCR)(24 months)
- Duration of response (DoR)(24 months)
- Progression-free survival (PFS)(24 months)
- 6-months/12-months OS rate(12 months)
- Adverse Events (AEs)(24 months)